Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
14
×
boston
14
×
boston blog main
boston top stories
14
×
life sciences
national blog main
san francisco blog main
14
×
national top stories
clinical trials
san francisco top stories
new york blog main
deals
fda
indiana blog main
san diego blog main
eli lilly
new york top stories
roche
genentech
indiana top stories
investing
medical devices
raleigh-durham blog main
seattle blog main
startups
vc
venture capital
wisconsin blog main
avapritinib
blueprint medicines
boston university
boulder/denver blog main
cancer
detroit blog main
dna
drug delivery
drugs
editas medicine
eventide asset management
gene editing
What
medicines
startup
therapeutics
ago
biotechs
drug
fda
genetic
ipos
medicine
patients
research
approval
biotech
blueprint
cancer
data
developing
device
drugs
editas
editing
experimental
gene
ipo
life
long
medical
million
morning
muscle
pact
ret
rna
roche
science
way
abandoning
abbvie
acquire
Language
unset
Current search:
biotech
×
boston
×
" boston top stories "
×
" san francisco blog main "
×
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
In Boston’s Shadow, Rhode Island Fights for Life Science Jobs, Respect
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M